Gilead Sciences cash flow statement

In fiscal 2025, Gilead Sciences's operations generated $10.02bn of cash; it spent $563m on capital projects, leaving free cash flow of $9.46bn. It returned $4.00bn in dividends and $1.92bn through buybacks.

Cash flow statement

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Gilead Sciences: cash flow statement, annual
Fiscal year	2009Dec 2009	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMSept 2026
Cash from operations	3.1	2.8	3.6	3.2	3.1	12.8	21.3	17.0	11.9	8.4	9.1	8.2	11.4	9.1	8.0	10.8	10.0	14.5
Depreciation and amortisation	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.3	0.3	0.3	0.3	0.4	0.4	0.4	0.4
Stock-based pay	0.2	0.2	0.2	0.2	0.3	0.4	0.4	0.4	0.6	0.8	0.6	0.6	0.6	0.6	0.8	0.8	0.9	0.9
Capital spending	0.2	0.1	0.1	0.4	0.1	0.6	0.7	0.7	0.6	0.9	0.8	0.7	0.6	0.7	0.6	0.5	0.6	0.7
Free cash flow	2.8	2.8	3.5	2.8	3.0	12.3	20.5	16.3	11.3	7.5	8.3	7.5	10.8	8.3	7.4	10.3	9.5	13.8
Free cash flow after stock pay	2.7	2.6	3.3	2.6	2.7	11.9	20.1	15.9	10.7	6.6	7.7	6.9	10.2	7.7	6.7	9.5	8.6	12.9
Dividends paid	—	—	—	—	0.0	0.0	1.9	2.5	2.7	3.0	3.2	3.4	3.6	3.7	3.8	3.9	4.0	4.1
Share buybacks	1.0	4.0	2.4	0.7	0.6	5.3	10.0	11.0	1.0	2.9	1.7	1.6	0.5	1.4	1.0	1.2	1.9	1.4
Shares issued	0.2	0.2	0.2	0.5	0.3	0.3	0.3	0.2	0.2	0.3	0.2	0.3	0.2	0.3	0.2	0.4	0.4	0.3

US$ millions unless shown otherwise. Fiscal quarters.

Gilead Sciences: cash flow statement, quarterly
Quarter	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026	2026 Q3Sept 2026
Cash from operations	2,975	1,757	827	4,108	3,327	2,544	3,573	5,035
Depreciation and amortisation	95	97	93	90	90	93	98	132
Stock-based pay	222	209	226	231	230	218	232	234
Capital spending	147	104	107	147	205	117	140	237
Free cash flow	2,828	1,653	720	3,961	3,122	2,427	3,433	4,798
Free cash flow after stock pay	2,606	1,444	494	3,730	2,892	2,209	3,201	4,564
Shares issued	173	252	27	97	32	166	9	87

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: AMGN vs GILD GILD vs REGN ABBV vs GILD

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Gilead Sciences's SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Gilead Sciences.